Manufacturers submit market authorisation applications in the EU and US for once-daily odevixibat for progressive familial intrahepatic cholestasis

Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) being developed to treat rare paediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis, biliary atresia and Alagille syndrome.

Source:

Biospace Inc.